Patents by Inventor Elissa A. Keogh

Elissa A. Keogh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-human Respiratory Syncytial Virus (RSV) antibodies and methods of use
    Patent number: 9988437
    Abstract: Provided herein are antibodies or antigen-binding fragments thereof that immunospecifically bind to the fusion (F) protein of Respiratory Syncytial Virus (RSV). Also provided are methods for of prevention, treatment and diagnosis of viral infection and/or the treatment of one more symptoms of RSV-mediated disease. Methods of generating antibodies that immunospecifically bind RSV F protein also are provided.
    Type: Grant
    Filed: March 22, 2016
    Date of Patent: June 5, 2018
    Assignee: Janssen Vaccines & Prevention B.V.
    Inventors: Robert Anthony Williamson, Jehangir Wadia, Gabriel Pascual, Elissa Keogh
  • Anti-human respiratory syncytial virus (RSV) antibodies and methods of use
    Patent number: 9403900
    Abstract: Provided herein are antibodies or antigen-binding fragments thereof that immunospecifically bind to the fusion (F) protein of Respiratory Syncytial Virus (RSV). Also provided are methods for of prevention, treatment and diagnosis of viral infection and/or the treatment of one more symptoms of RSV-mediated disease. Methods of generating antibodies that immunospecifically bind RSV F protein also are provided.
    Type: Grant
    Filed: June 5, 2014
    Date of Patent: August 2, 2016
    Assignee: Crucell Holland B.V.
    Inventors: Robert Anthony Williamson, Jehangir Wadia, Gabriel Pascual, Elissa Keogh
  • ANTI-HUMAN RESPIRATORY SYNCYTIAL VIRUS (RSV) ANTIBODIES AND METHODS OF USE
    Publication number: 20160194383
    Abstract: Provided herein are antibodies or antigen-binding fragments thereof that immunospecifically bind to the fusion (F) protein of Respiratory Syncytial Virus (RSV). Also provided are methods for of prevention, treatment and diagnosis of viral infection and/or the treatment of one more symptoms of RSV-mediated disease. Methods of generating antibodies that immunospecifically bind RSV F protein also are provided.
    Type: Application
    Filed: March 22, 2016
    Publication date: July 7, 2016
    Inventors: Robert Anthony Williamson, Jehangir Wadia, Gabriel Pascual, Elissa Keogh
  • Antibodies against human respiratory syncytial virus (RSV) and methods of use
    Patent number: 9365638
    Abstract: Provided herein are antibodies or antigen-binding fragments thereof that immunospecifically bind to the fusion (F) protein of Respiratory Syncytial Virus (RSV). Also provided are methods for of prevention, treatment and diagnosis of viral infection and/or the treatment of one more symptoms of RSV-mediated disease. Methods of generating antibodies that immunospecifically bind RSV F protein also are provided.
    Type: Grant
    Filed: September 10, 2013
    Date of Patent: June 14, 2016
    Assignee: Crucell Holland B. V.
    Inventors: Robert Anthony Williamson, Jehangir Wadia, Gabriel Pascual, Elissa Keogh
  • Anti-human respiratory syncytial virus (RSV) antibodies and methods of use
    Patent number: 9139642
    Abstract: Provided herein are antibodies or antigen-binding fragments thereof that immunospecifically bind to the fusion (F) protein of Respiratory Syncytial Virus (RSV). Also provided are methods for of prevention, treatment and diagnosis of viral infection and/or the treatment of one more symptoms of RSV-mediated disease. Methods of generating antibodies that immunospecifically bind RSV F protein also are provided.
    Type: Grant
    Filed: July 8, 2011
    Date of Patent: September 22, 2015
    Assignee: Crucell Holland B.V.
    Inventors: Robert Anthony Williamson, Jehangir Wadia, Gabriel Pascual, Elissa Keogh
  • ANTI-HUMAN RESPIRATORY SYNCYTIAL VIRUS (RSV) ANTIBODIES AND METHODS OF USE
    Publication number: 20140363427
    Abstract: Provided herein are antibodies or antigen-binding fragments thereof that immunospecifically bind to the fusion (F) protein of Respiratory Syncytial Virus (RSV). Also provided are methods for of prevention, treatment and diagnosis of viral infection and/or the treatment of one more symptoms of RSV-mediated disease. Methods of generating antibodies that immunospecifically bind RSV F protein also are provided.
    Type: Application
    Filed: June 5, 2014
    Publication date: December 11, 2014
    Inventors: Robert Anthony Williamson, Jehangir Wadia, Gabriel Pascual, Elissa Keogh
  • HLA CLASS I A2 TUMOR ASSOCIATED ANTIGEN PEPTIDES AND VACCINE COMPOSITIONS
    Publication number: 20140147490
    Abstract: A composition or vaccine composition comprising at least one peptide that has less than 600 contiguous amino acids having 100% identity to a native sequence of CEA, HER2/neu, MAGE2, MAGE3, or p53, the peptide further comprising at least one epitope selected from Table 6.
    Type: Application
    Filed: October 29, 2012
    Publication date: May 29, 2014
    Inventors: John D. Fikes, Alessandro Sette, John Sidney, Scott Southwood, Esteban Celis, Elissa A. Keogh, Robert Chesnut
  • Antibodies against human respiratory syncytial virus (RSV) and methods of use
    Patent number: 8568719
    Abstract: Provided herein are antibodies or antigen-binding fragments thereof that immunospecifically bind to the fusion (F) protein of Respiratory Syncytial Virus (RSV). Also provided are methods for of prevention, treatment and diagnosis of viral infection and/or the treatment of one more symptoms of RSV-mediated disease. Methods of generating antibodies that immunospecifically bind RSV F protein also are provided.
    Type: Grant
    Filed: August 13, 2010
    Date of Patent: October 29, 2013
    Assignee: Crucell Holland B.V.
    Inventors: Robert Anthony Williamson, Jehangir Wadia, Gabriel Pascual, Elissa Keogh
  • ANTI-HUMAN RESPIRATORY SYNCYTIAL VIRUS (RSV) ANTIBODIES AND METHODS OF USE
    Publication number: 20130177573
    Abstract: Provided herein are antibodies or antigen-binding fragments thereof that immunospecifically bind to the fusion (F) protein of Respiratory Syncytial Virus (RSV). Also provided are methods for of prevention, treatment and diagnosis of viral infection and/or the treatment of one more symptoms of RSV-mediated disease. Methods of generating antibodies that immunospecifically bind RSV F protein also are provided.
    Type: Application
    Filed: July 8, 2011
    Publication date: July 11, 2013
    Inventors: Robert Anthony Williamson, Jehangir Wadia, Gabriel Pascual, Elissa Keogh
  • HLA CLASS I A2 TUMOR ASSOCIATED ANTIGEN PEPTIDES AND VACCINE COMPOSITIONS
    Publication number: 20110318408
    Abstract: A composition or vaccine composition comprising at least one peptide that has less than 600 contiguous amino acids having 100% identity to a native sequence of CEA, HER2/neu, MAGE2, MAGE3, or p53, the peptide further comprising at least one epitope selected from Table 6.
    Type: Application
    Filed: June 7, 2011
    Publication date: December 29, 2011
    Inventors: John D. Fikes, Alessandro Sette, John Sidney, Scott Southwood, Esteban Celis, Elissa A. Keogh, Robert Chesnut
  • Antibodies against human respiratory syncytial virus (RSV) and methods of use
    Publication number: 20110076268
    Abstract: Provided herein are antibodies or antigen-binding fragments thereof that immunospecifically bind to the fusion (F) protein of Respiratory Syncytial Virus (RSV). Also provided are methods for of prevention, treatment and diagnosis of viral infection and/or the treatment of one more symptoms of RSV-mediated disease. Methods of generating antibodies that immunospecifically bind RSV F protein also are provided.
    Type: Application
    Filed: August 13, 2010
    Publication date: March 31, 2011
    Inventors: ROBERT ANTHONY WILLIAMSON, JEHANGIR WADIA, GABRIEL PASCUAL, ELISSA KEOGH
  • HLA class I A2 tumor associated antigen peptides and vaccine compositions
    Publication number: 20080279924
    Abstract: A composition or vaccine composition comprising at least one peptide that has less than 600 contiguous amino acids having 100% identity to a native sequence of CEA, HER2/neu, MAGE2, MAGE3, or p53, the peptide further comprising at least one epitope selected from Table 6.
    Type: Application
    Filed: October 29, 2007
    Publication date: November 13, 2008
    Inventors: John D. Fikes, Alessandro Sette, John Sidney, Scott Southwood, Esteban Celis, Elissa A. Keogh, Robert Chesnut
  • HLA class I A2 tumor associated antigen peptides and vaccine compositions
    Publication number: 20070098776
    Abstract: A composition or vaccine composition comprising at least one peptide that has less than 600 contiguous amino acids having 100% identity to a native sequence of CEA, HER2/neu, MAGE2, MAGE3, or p53, the peptide further comprising at least one epitope selected from Table 6.
    Type: Application
    Filed: July 10, 2006
    Publication date: May 3, 2007
    Inventors: John Fikes, Alessandro Sette, John Sidney, Scott Southwood, Esteban Celis, Elissa Keogh, Robert Chesnut
  • Inducing cellular immune responses to prostate cancer antigens using peptide and nucleic acid compositions
    Publication number: 20070020327
    Abstract: This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and prepare prostate cancer-associated antigen epitopes, and to develop epitope-based vaccines directed towards prostate tumors. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of cancer.
    Type: Application
    Filed: May 5, 2006
    Publication date: January 25, 2007
    Inventors: John Fikes, Alessandro Sette, John Sidney, Scott Southwood, Robert Chesnut, Esteban Celis, Elissa Keogh
  • Hla-a1,-a2,-a3,-a24,-b7, and-b44 tumor associated antigen peptides and compositions
    Publication number: 20060094649
    Abstract: A peptide or composition comprising at least one epitope or analog from CEA, HER2/neu, MAGE2, MAGE3, or p53.
    Type: Application
    Filed: December 10, 2003
    Publication date: May 4, 2006
    Inventors: Elissa Keogh, Scott Southwood, John Fikes, Alessandro Sette
  • Inducing cellular immune responses to p53 using peptide and nucleic acid compositions
    Publication number: 20050196403
    Abstract: This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and prepare p53 epitopes, and to develop epitope-based vaccines directed towards p53-bearing tumors. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of cancer.
    Type: Application
    Filed: February 7, 2005
    Publication date: September 8, 2005
    Inventors: John Fikes, Alessandro Sette, John Sidney, Scott Southwood, Robert Chesnut, Esteban Celis, Elissa Keogh
  • Inducing cellular immune responses to carcinoembryonic antigen using peptide and nucleic acid compositions
    Publication number: 20040146519
    Abstract: This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and prepare carcino-embryonic antigen (CEA) epitopes, and to develop epitope-based vaccines directed towards CEA-bearing tumors. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of cancer.
    Type: Application
    Filed: October 22, 2002
    Publication date: July 29, 2004
    Inventors: John Fikes, Alessandro Sette, John Sidney, Scott Southwood, Robert Chesnut, Esteban Celis, Elissa Keogh
  • Inducing cellular immune responses to her2/neu using peptide and nucleic acid compositions
    Publication number: 20040121946
    Abstract: This invention uses our knoeledge of the mechanisms by which antigen is recognized by T cells to identify and prepare HER2/neu epitopes, and to develop epitope-based vaccines directed towards HERS2/neu-bearing tumors. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of cancer.
    Type: Application
    Filed: October 24, 2002
    Publication date: June 24, 2004
    Inventors: John Fikes, Alessandro Sette, John Sydney, Scott Southwood, Robert Chesnut, Esteban Celis, Elissa Keogh
  • Inducing cellular immune responses to mage2/3 using peptide and nucleic acid compositions
    Publication number: 20040053822
    Abstract: The invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and prepare MAGE2/3 epitopes, and to develop epitope-based vaccines directed towards MAGE2/3-bearing tumors. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use it) the prevention and treatment of cancer.
    Type: Application
    Filed: October 21, 2002
    Publication date: March 18, 2004
    Inventors: John Fikes, Alessandro Sette, John Sidney, Scott Southwood, Robert Chesnut, Esteban Celis, Elissa Keogh
  • Inducing cellular immune responses to p53 using peptide and nucleic acid compositions
    Publication number: 20040048790
    Abstract: This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and prepare p53 epitopes, and to develop epitope-based vaccines directed towards p53-bearing tumors. More specifically, this application communicates our discovery of pharmnaceutical compositions and methods of use in the prevention and treatment of cancer.
    Type: Application
    Filed: November 18, 2002
    Publication date: March 11, 2004
    Inventors: John Fikes, Alessandro Sette, John Sidney, Scott Southwood, Robert Chesnut, Esteban Celis, Elissa Keogh